News

Article

EMPOWERing the Next Generation

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

CONFERENCE REPORTER

Erica Koenig, PhD, gives an overview of Cerevel Therapeutics and discusses EMPOWER, a phase 2 clinical trial evaluating emraclidine for the treatment of schizophrenia. Koenig presented this research in a poster presentation at Psych Congress 2023.

Dr Koenig is program lead of emraclidine and senior director of global clinical development at Cerevel Therapeutics.

Related Videos
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
ADHD
brain depression
brain
nicotine use
brain schizophrenia
eating disorder brain
dementia
schizophrenia
© 2024 MJH Life Sciences

All rights reserved.